The data indicate that carrageenan acts in synergism with obesity and possibly other factors, such as an altered microbiome, in at-risk individuals to further disrupt the intestinal barrier, exaggerate systemic inflammation, and increase insulin resistance. The gene discussed is INS; the disease is obesity due to melanocortin 4 receptor deficiency.